Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) presented the differentiated profile of opamtistomig (LBL-024) to global pharmaceutical companies and investors ...
DXS International plc (“the Company” or “DXSP”), the UK healthcare technology provider, is pleased to announce that all resolutions put to shareholders at the Company's Annual General Meeting ("AGM") ...
Louvain-la-Neuve, Belgium, November 20, 2026, 7 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for ...
That is why Assurion Labs reports net peptide content on every COA. Impurities that HPLC does detect, such as truncated or deletion sequences from synthesis, are kept at or below 1% combined.
The merger with Treeline is expected to close in the fourth quarter of 2026, subject to the satisfaction of remaining customary closing conditions. The sale of the Mass Cytometry business is expected ...
Results support the ongoing Phase 3 RASolute 303 trial in patients with treatment-naïve metastatic pancreatic cancer ...
New interim results from the U.S. REGAIN recurrent glioblastoma trial presented at the SNO 2026 Annual Meeting: all eight treated patients alive, with median overall survival not reached, and a 100% ...
Investors interested in listening to the conference call may do so by registering at this link: SI-BONE, Inc. (SIBN) - 1781908. Live audio of the webcast will be available on the “Investors” section ...
Phase 3 barzolvolimab cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively enrolling ...
Azora Therapeutics, Inc. (NASDAQ: AZR) (the “Company”), a biopharmaceutical company developing treatments for serious inflammatory diseases, announced today that the Compensation Committee of its ...
The MGMA Board of Directors announced today that Chris DeRienzo, MD, MPP, will serve as the association’s next Chief Executive Officer, effective January 4, 2027. The Board selected DeRienzo following ...
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results